164 related articles for article (PubMed ID: 22013037)
1. Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.
Horst D; Burrows SR; Gatherer D; van Wilgenburg B; Bell MJ; Boer IG; Ressing ME; Wiertz EJ
J Virol; 2012 Jan; 86(1):572-7. PubMed ID: 22013037
[TBL] [Abstract][Full Text] [Related]
2. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
[TBL] [Abstract][Full Text] [Related]
3. Latent Expression of the Epstein-Barr Virus (EBV)-Encoded Major Histocompatibility Complex Class I TAP Inhibitor, BNLF2a, in EBV-Positive Gastric Carcinomas.
Strong MJ; Laskow T; Nakhoul H; Blanchard E; Liu Y; Wang X; Baddoo M; Lin Z; Yin Q; Flemington EK
J Virol; 2015 Oct; 89(19):10110-4. PubMed ID: 26178981
[TBL] [Abstract][Full Text] [Related]
4. EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.
Horst D; Favaloro V; Vilardi F; van Leeuwen HC; Garstka MA; Hislop AD; Rabu C; Kremmer E; Rickinson AB; High S; Dobberstein B; Ressing ME; Wiertz EJ
J Immunol; 2011 Mar; 186(6):3594-605. PubMed ID: 21296983
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.
Horst D; van Leeuwen D; Croft NP; Garstka MA; Hislop AD; Kremmer E; Rickinson AB; Wiertz EJ; Ressing ME
J Immunol; 2009 Feb; 182(4):2313-24. PubMed ID: 19201886
[TBL] [Abstract][Full Text] [Related]
6. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
Jochum S; Moosmann A; Lang S; Hammerschmidt W; Zeidler R
PLoS Pathog; 2012; 8(5):e1002704. PubMed ID: 22615564
[TBL] [Abstract][Full Text] [Related]
7. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.
Bell MJ; Abbott RJ; Croft NP; Hislop AD; Burrows SR
J Virol; 2009 Mar; 83(6):2783-8. PubMed ID: 19129449
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
9. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
[TBL] [Abstract][Full Text] [Related]
10. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
11. Sequence analysis of EBV immune evasion gene BNLF2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic and non-endemic regions of China.
Liu S; Wang X; Shu J; Zhao Z; Sun Z; Luo B
J Med Virol; 2015 Nov; 87(11):1946-52. PubMed ID: 25959517
[TBL] [Abstract][Full Text] [Related]
12. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP.
Wycisk AI; Lin J; Loch S; Hobohm K; Funke J; Wieneke R; Koch J; Skach WR; Mayerhofer PU; Tampé R
J Biol Chem; 2011 Dec; 286(48):41402-41412. PubMed ID: 21984826
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.
Almohammed R; Osborn K; Ramasubramanyan S; Perez-Fernandez IBN; Godfrey A; Mancini EJ; Sinclair AJ
J Gen Virol; 2018 Jun; 99(6):805-817. PubMed ID: 29580369
[TBL] [Abstract][Full Text] [Related]
15. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
[TBL] [Abstract][Full Text] [Related]
16. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
18. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
Ressing ME; Keating SE; van Leeuwen D; Koppers-Lalic D; Pappworth IY; Wiertz EJ; Rowe M
J Immunol; 2005 Jun; 174(11):6829-38. PubMed ID: 15905524
[TBL] [Abstract][Full Text] [Related]
19. The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines.
Ong KW; Wilson AD; Hirst TR; Morgan AJ
J Virol; 2003 Apr; 77(7):4298-305. PubMed ID: 12634387
[TBL] [Abstract][Full Text] [Related]
20. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution.
Burrows JM; Burrows SR; Poulsen LM; Sculley TB; Moss DJ; Khanna R
J Virol; 1996 Apr; 70(4):2490-6. PubMed ID: 8642677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
